Mast Therapeutics Begins Phase 2 Study for Vepoloxamer

Biotech Investing

Mast Therapeutics, Inc. (NYSE MKT:MSTX) has begun its Phase 2 study of vepoloxamer for the treatment of patients with chronic heart failure.

Mast Therapeutics, Inc. (NYSE MKT:MSTX) has begun its Phase 2 study of vepoloxamer for the treatment of patients with chronic heart failure.
According to the press release:

Dr. Edwin L. Parsley, Chief Medical Officer of the Company, said: “Previously-announced positive results from multiple randomized, placebo-controlled studies of vepoloxamer in a well-established model of chronic heart failure, including a repeat-treatment study, as well as recommendations from medical experts in the field, strongly support clinical development of vepoloxamer in this setting. If the promising results observed in non-clinical studies translate to patients with chronic heart failure, vepoloxamer may offer a novel way of directly improving left ventricle contractile function by restoring cardiomyocyte membrane integrity and increasing cardiomyocyte survival. Significantly, in this Phase 2 study, vepoloxamer will be administered over 3 hours in an outpatient setting, as opposed to the 49-hour administration in our sickle cell disease studies, which will help demonstrate its practical utility for chronic heart failure patients. We intend to collect echocardiographic data on parameters such as ejection fraction as well as biomarkers associated with clinical outcomes such as ultra-high sensitivity troponin I and NT-proBNP, as these metrics were improved in a statistically significantly manner in previously-announced heart failure models.”

Click here to read the full press release.


 
The Conversation (0)
×